YM BioSciences says AeroLEF provides efficient pain relief

AeroLEF is a unique inhaled-delivery system in development for the treatment of moderate to severe pain, including cancer pain. AeroLEF is designed to permit patients to match dosage to their individual pain intensity.

“The time course of analgesia demonstrated in this study suggests that AeroLEF is suitable for the stabilization of acute post-operative pain,” said Sugantha Ganapathy, director of regional anesthesia, University of Western Ontario.

“Furthermore, differences in median times to effective analgesia for patients taking second and third doses of AeroLEF suggests that patients were capable of safely self-limiting dosing to match the intensity of each pain episode.”

In the study, patient self-titrated dosing with AeroLEF provided clinically meaningful analgesia in 81%, 100% and 87.5% of treated pain episodes during doses 1, 2 and 3 respectively. Study results also suggested that multiple doses of AeroLEF were well tolerated.

“We continue to enroll patients in the randomized portion of the trial based on an interim analysis that showed benefit versus placebo,” said David Allan, chairman and CEO of YM BioSciences.